Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. TREM2 and immune genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Neuroinflammation precedes the clinical onset of various neurodegenerative diseases, including Alzheimer's disease (AD), by years or frequently even decades (1-3). In terms of the underlying physiology, there is a great need for understanding and controlling interactions between the central nervous system (CNS) and the immune system in an attempt to develop approaches to prevent or delay the disease's progression. Nerve cells have limited motion capability, whereas immune cells can migrate freely via circulation.

What this study adds

Evidence grade: Low

This review says neuroinflammation can begin years or even decades before Alzheimer's symptoms appear, and that more must be learned about how the nervous and immune systems interact. It does not report any treatment, cure or prevention that works; it only argues that understanding these interactions is needed to try to prevent or delay progression.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kiraly, M., Foss, J. F., & Giordano, T. (2023). Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2023.109

Vancouver

Kiraly M, Foss JF, Giordano T. Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie. The journal of prevention of Alzheimer's disease. 2023. doi:10.14283/jpad.2023.109. PMID: 37874089.

BibTeX

@article{kiraly2023-37874089,
  author  = {Kiraly, M. and Foss, J. F. and Giordano, T.},
  title   = {{Neuroinflammation, its Role in Alzheimer's Disease and Therapeutic Strategie}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.109},
  pmid    = {37874089},
  url     = {https://doi.org/10.14283/jpad.2023.109}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review says neuroinflammation can begin years or even decades before Alzheimer's symptoms appear, and that more must be learned about how the nervous and immune systems interact. It does not report any treatment, cure or prevention that works; it only argues that understanding these interactions is needed to try to prevent or delay progression.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 38 of the 93 points it could be judged on, which is 41 of 100. Total 41 of 100.38 of the 93 points we could judge = 41 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 38 of the 93 points we could judge it on, which is 41 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 93 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 18.6 citations a year over 5 year(s) since 2023
Impact for its field and year 3 / 6 Cited 7.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 3 / 4 Cited 93 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37874089)
Free to read 0 / 2 Behind a paywall — scores zero
Points 38 / 93 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 38 of the 93 points we could judge it on is 41 out of 100.
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in TREM2 and immune genetics from nearby years

Also in TREM2 and immune genetics

83 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →